Lin Shao-Lee
Lin Shao-Lee, CEO, reported an open-market or private sale at Cue Biopharma, Inc. involving 1087.000000 shares for an estimated $30490.35. Reported holdings after the transaction were 694908.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
- Trade date
- Oct 12, 2026
- Filing date
- Oct 15, 2026
How reported position traded is calculated
Shares sold ÷ (holdings after + shares sold). Estimated position before: 695,995 shares.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
CUE price since this filing
Daily closing prices, with the filing date and available return windowsTransaction facts
Stored Form 4 columns with their raw values
- Type
- Sell Code S
- Identifier
- 0001725092-26-000019 Common Stock
- Transaction date
- Oct 12, 2026 Filed Oct 15, 2026, 01:37 AM · 3d delay
- Shares
- 1,087 sh $28.05 per share
- Estimated value
- -$30.4k Computed from shares × price
- Holdings after
- 694,908 sh Direct
Filing signal explanations
Badges describe filing facts only — not predictions.
+6 points
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a modest positive filing-only score. Treat it as a useful flag for review, not as a buy signal.
How this score is calculated
- direct_ownership+6 points
direct_or_indirect_ownership = D
Direct ownership reports the insider's personal stake.
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
Chief Executive Officer
- F1
The sales reported represent shares sold pursuant to the Issuer's Company-Wide Policy and do not represent discretionary transactions by the Reporting Person. These sales were made automatically to sa…
0 other transactions
0 recent txs